Cutting edge: Mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 44-48

  Phelan, James D ^a   Orekov, Tatyana ^a,b   Finkelman, Fred D ^a,b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BVD4.1D11; MONOCLONAL ANTIBODY S4B6; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HALF LIFE TIME; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; FEMALE; HALF-LIFE; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 40449139771     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.44     Document Type: Article

References (20)

1. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
2. Lipsky, P. E., D. M. van der Heijde, E. W. St. Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343: 1594-1602.
3. Hochberg, M. C., J. K. Tracy, M. Hawkins-Holt, and R. H. Flores. 2003. Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 (Suppl. 2): ii13-ii16.
4. Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Furst, M. H. Weisman, E. W. St. Clair, G. F. Keenan, D. van der Heijde, P. A. Marsters, and P. E. Lipsky. 2004. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50: 1051-1065.
5. Samuels, J., and S. Ozen. 2006. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr. Opin. Rheumatol. 18: 108-117.
6. van Dullemen, H. M., S. J. van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
7. Haraoui, B. 2005. Differentiating the efficacy of tumor necrosis factor inhibitors. J. Rheumatol. Suppl. 74: 3-7.
8. Malek, T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukocyte Biol. 74: 961-965.
9. Malek, T. R., and A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674.
10. Boyman, O., M. Kovar, M. P. Rubinstein, C. D. Surh, and J. Sprent. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
11. + suppressor T cells. Immunol. Rev. 182: 58-67.
12. Leonard, W. J., J. M. Depper, G. R. Crabtree, S. Rudikoff, J. Pumphrey, R. J. Robb, M. Kronke, P. B. Svetlik, N. J. Peffer, T. A. Waldmann, et al. 1984. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626-631.
13. Leonard, W. J., M. Kronke, N. J. Peffer, J. M. Depper, and W. C. Greene. 1985. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc. Natl. Acad. Sci. USA 82: 6281-6285.
14. Robb, R. J., A. Munck, and K. A. Smith. 1981. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J. Exp. Med. 154: 1455-1474.
15. Nakamura, Y., S. M. Russell, S. A. Mess, M. Friedmann, M. Erdos, C. Francois, Y. Jacques, S. Adelstein, and W. J. Leonard. 1994. Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling. Nature 369: 330-333.
16. Finkelman, F. D., K. B. Madden, S. C. Morris, J. M. Holmes, N. Boiani, I. M. Katona, and C. R. Maliszewski. 1993. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151: 1235-1244.
17. Ghetie, V., and E. S. Ward. 2000. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol. 18: 739-766.
18. 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J. Immunol. 154: 6246-6251.
19. Waldmann, T. A., and W. Strober. 1969. Metabolism of immunoglobulins. Prog. Allergy. 13: 1-110.
20. Baraliakos, X., J. Listing, J. Brandt, A. Zink, R. Alten, G. Burmester, E. Gromnica-Ihle, H. Kellner, M. Schneider, H. Sorensen, et al. 2005. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arth. Res. Ther. 7: R439-R444.